PHASE II TRIAL OF AKT INHIBITOR MK-2206 IN PATIENTS WITH ADVANCED BREAST CANCER WHO HAVE TUMORS WITH PIK3CA OR AKT MUTATIONS, AND/OR PTEN LOSS/PTEN MUTATION

Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation

Abstract Background The PI3K/AKT pathway is activated through PIK3CA or AKT1 mutations and PTEN loss in breast cancer.We conducted a phase II trial with an allosteric AKT inhibitor MK-2206 in patients with advanced GLOST BOND HAIR GLUE breast cancer who had tumors with PIK3CA/AKT1 mutations and/or PTEN loss/mutation.Methods The primary endpoint was

read more